ATTENTION: The software behind KU ScholarWorks is going to be upgraded to a new version toward the end of July. Starting July 15th, users will not be able to log in to the system until the new version is in place. Searching for articles and opening files will continue to work while the system is being updated. If you have any questions, please contact Marianne Reed at mreed@ku.edu .

Show simple item record

dc.contributor.authorLominska, Chris E
dc.contributor.authorUnger, Keith
dc.contributor.authorNasr, Nadim M
dc.contributor.authorHaddad, Nadim
dc.contributor.authorGagnon, Greg
dc.date.accessioned2015-05-27T09:52:02Z
dc.date.available2015-05-27T09:52:02Z
dc.date.issued2012-05-18en_US
dc.identifier.urihttp://hdl.handle.net/2271/1324en_US
dc.description.abstractAbstractBackgroundLocal control rates are poor in the treatment of pancreatic cancer. We investigated the role of hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses of external beam radiation therapy.MethodsAll patients treated with SBRT for pancreatic adenocarcinoma at Georgetown University from June 2002 through July 2007 were examined. Eligible patients had prior external beam radiation therapy to the pancreas. Treatment parameters and clinical and radiographic follow-up were evaluated.ResultsTwenty-eight patients were identified who received SBRT after a median prior external beam radiotherapy dose of 50.4 Gy. The median patient age was 63 years old and the median follow-up was 5.9 months. Twelve of fourteen (85.7%) evaluable patients were free from local progression, with three partial responses and nine patients with stable disease. Toxicity consisted of one case of acute Grade II nausea/vomiting, and two cases of Grade III late GI toxicity. The median overall survival was 5.9 months, with 18% survival and 70% freedom from local progression at one year.ConclusionsHypofractionated SBRT reirradiation of localized pancreatic cancer is a well-tolerated treatment. Most patients are free from local progression, albeit with limited follow-up, but overall survival remains poor.
dc.titleStereotactic Body Radiation Therapy for Reirradiation of Localized Adenocarcinoma of the Pancreas
dc.typeArticleen_US
dc.identifier.doi10.1186/1748-717X-7-74en_US
dc.date.updated2012-09-12T15:06:46Z
dc.description.versionPeer Reviewed
dc.rights.holderChris E Lominska et al.; licensee BioMed Central Ltd.
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record